Arena Looks To Partnering Strategy While Hoping For Belviq Resurrection

The firm's entire pipeline is up for partnering, interim CEO Hixson says, while Arena awaits CV outcomes data and approval of an extended-release version of Belviq.

While awaiting cardiovascular outcomes data that it believes could spark renewed interest and sales in its obesity drug Belviq, Arena Pharmaceuticals Inc. is looking for a new CEO and offering its entire pipeline out for partnering opportunities, the troubled specialty firm said during a Feb. 29 earnings call.

In the wake of consistently disappointing sales for its obesity drug, once expected to yield blockbuster sales, Arena's board asked...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By 

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

Drug Sponsors Can Help Shape Agenda For FDA/EMA Pediatric ‘Cluster’ Calls

 
• By 

Companies can propose specific issues for discussion during the regulators’ monthly teleconferences, which focus on finding areas of agreement and reasons for nonalignment on specific pediatric development plans or general issues.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.